Sulodexide, also known as sulodexidum, a medication that is a highly purified mixture of glycosaminoglycans (GAGs) derived from porcine intestinal mucosa.
It typically consists of: 80% heparan sulfate (fast-moving heparin fraction) 20% dermatan sulfate.
Sulodexide is a highly purified mixture of glycosaminoglycans (80% heparan sulfate and 20% dermatan sulfate) prescribed to treat vascular conditions.
It has antithrombotic, profibrinolytic, and endothelial-protective properties.
It is primarily used to treat chronic venous disease, heal venous ulcers, and prevent recurrent blood clots.
It has antithrombotic (anti-clotting), endothelial-protective, anti-inflammatory, and lipid-lowering properties.
Unlike standard heparin, it has good oral bioavailability and a lower risk of bleeding complications.
Main Uses Vascular diseases: Prophylaxis and treatment of conditions with high thrombosis risk, such as chronic venous insufficiency (CVI), venous ulcers, post-thrombotic syndrome (PTS), peripheral arterial disease, and intermittent claudication.
Chronic Venous Disease (CVD): Reduces symptoms like leg pain, swelling, heaviness, and cramping.
Venous Leg Ulcers: Promotes healing of chronic sores or wounds caused by poor blood circulation.
Thrombosis Prevention: Used in the prophylaxis and management of venous thromboembolism (VTE) to prevent recurrent blood clots.
Diabetic Nephropathy: Helps stabilize kidney function and reduce protein leakage (albuminuria) in diabetic patients.
Investigated for long COVID-related coagulation issues and cognitive/vascular protection in some contexts.
Mechanism of Action
Anticoagulant effect: Inhibits thrombin and reduces the likelihood of blood clots forming.
Profibrinolytic activity: Promotes the release of tissue plasminogen activator, which helps dissolve existing clots.
Endothelial protection: Protects the inner lining of blood vessels (the endothelium) and reduces inflammation.
Available in oral capsules, injectable forms, or other preparations in many countries.
It is not FDA-approved in the United States.
It potentiates antithrombin III and heparin cofactor II, helps regulate endothelial function, reduces inflammation, and has a milder effect on systemic coagulation compared to full-dose heparins.
Not FDA Approved: Sulodexide is widely used in Europe, South America, and Asia.
Dosage: It is generally available in oral capsule form (typically 250 LSU) and sometimes as an injectable solution (600 LSU) for initial parenteral treatment before switching to oral pills.
Sulodexide is known for having a lower risk of major bleeding complications compared to standard heparin.
Minor side effects can include:
Nausea, dyspepsia, or other mild gastrointestinal upset.
Pain or burning at the injection site,